Shield Therapeutics Sees Significant Revenue Growth Amidst US Market Expansion Business 4 September 2024 In the first half of the year, Shield Therapeutics experienced over threefold revenue growth, reaching $12.1 million. The company focuses…
Shield Therapeutics Gains Ground in Canada with Iron Deficiency Medication Approval Business 27 August 2024 Shield Therapeutics has successfully gained approval from Health Canada for its ground-breaking Accrufer tablets. This development marks a significant step…
CEO Transition at Shield Therapeutics Amidst Growing US Market Presence Business 24 July 2024 Shield Therapeutics has undergone a significant leadership change, marking a new chapter for the company. Greg Madison, who led the…
